Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing
“Lock-in” programs are used by health insurers to reduce the risk of adverse outcomes that can result from overutilization of opioids and other controlled substances. We estimated the association between North Carolina’s Medicaid lock-in program and use of opioid use disorder treatment-related servi...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Naumann, Rebecca B. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Statistical analysis to identify biomarkers for safety - Clark, Matthew ELSEVIER, 2018, an international journal on biomedical and psychosocial approaches, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:233 ; year:2022 ; day:1 ; month:04 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.drugalcdep.2022.109385 |
|---|
| Katalog-ID: |
ELV057207119 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV057207119 | ||
| 003 | DE-627 | ||
| 005 | 20230625001147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220808s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drugalcdep.2022.109385 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001760.pica |
| 035 | |a (DE-627)ELV057207119 | ||
| 035 | |a (ELSEVIER)S0376-8716(22)00122-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.38 |2 bkl | ||
| 084 | |a 44.39 |2 bkl | ||
| 100 | 1 | |a Naumann, Rebecca B. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing |
| 264 | 1 | |c 2022 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a “Lock-in” programs are used by health insurers to reduce the risk of adverse outcomes that can result from overutilization of opioids and other controlled substances. We estimated the association between North Carolina’s Medicaid lock-in program and use of opioid use disorder treatment-related services and naloxone dispensing. | ||
| 650 | 7 | |a Lock-in |2 Elsevier | |
| 650 | 7 | |a Beneficiary management |2 Elsevier | |
| 650 | 7 | |a Naloxone |2 Elsevier | |
| 650 | 7 | |a Treatment |2 Elsevier | |
| 650 | 7 | |a Patient review and restriction |2 Elsevier | |
| 650 | 7 | |a Opioid |2 Elsevier | |
| 700 | 1 | |a Austin, Anna E. |4 oth | |
| 700 | 1 | |a Wang, Lily |4 oth | |
| 700 | 1 | |a Roberts, Andrew W. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Clark, Matthew ELSEVIER |t Statistical analysis to identify biomarkers for safety |d 2018 |d an international journal on biomedical and psychosocial approaches |g Amsterdam [u.a.] |w (DE-627)ELV000553670 |
| 773 | 1 | 8 | |g volume:233 |g year:2022 |g day:1 |g month:04 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.drugalcdep.2022.109385 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.38 |j Pharmakologie |q VZ |
| 936 | b | k | |a 44.39 |j Toxikologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 233 |j 2022 |b 1 |c 0401 |h 0 | ||
| author_variant |
r b n rb rbn |
|---|---|
| matchkey_str |
naumannrebeccabaustinannaewanglilyrobert:2022----:matoaeiadoknrgaooiiueiodrramnadev |
| hierarchy_sort_str |
2022 |
| bklnumber |
44.38 44.39 |
| publishDate |
2022 |
| allfields |
10.1016/j.drugalcdep.2022.109385 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001760.pica (DE-627)ELV057207119 (ELSEVIER)S0376-8716(22)00122-3 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl Naumann, Rebecca B. verfasserin aut Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier “Lock-in” programs are used by health insurers to reduce the risk of adverse outcomes that can result from overutilization of opioids and other controlled substances. We estimated the association between North Carolina’s Medicaid lock-in program and use of opioid use disorder treatment-related services and naloxone dispensing. Lock-in Elsevier Beneficiary management Elsevier Naloxone Elsevier Treatment Elsevier Patient review and restriction Elsevier Opioid Elsevier Austin, Anna E. oth Wang, Lily oth Roberts, Andrew W. oth Enthalten in Elsevier Science Clark, Matthew ELSEVIER Statistical analysis to identify biomarkers for safety 2018 an international journal on biomedical and psychosocial approaches Amsterdam [u.a.] (DE-627)ELV000553670 volume:233 year:2022 day:1 month:04 pages:0 https://doi.org/10.1016/j.drugalcdep.2022.109385 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ 44.39 Toxikologie VZ AR 233 2022 1 0401 0 |
| spelling |
10.1016/j.drugalcdep.2022.109385 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001760.pica (DE-627)ELV057207119 (ELSEVIER)S0376-8716(22)00122-3 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl Naumann, Rebecca B. verfasserin aut Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier “Lock-in” programs are used by health insurers to reduce the risk of adverse outcomes that can result from overutilization of opioids and other controlled substances. We estimated the association between North Carolina’s Medicaid lock-in program and use of opioid use disorder treatment-related services and naloxone dispensing. Lock-in Elsevier Beneficiary management Elsevier Naloxone Elsevier Treatment Elsevier Patient review and restriction Elsevier Opioid Elsevier Austin, Anna E. oth Wang, Lily oth Roberts, Andrew W. oth Enthalten in Elsevier Science Clark, Matthew ELSEVIER Statistical analysis to identify biomarkers for safety 2018 an international journal on biomedical and psychosocial approaches Amsterdam [u.a.] (DE-627)ELV000553670 volume:233 year:2022 day:1 month:04 pages:0 https://doi.org/10.1016/j.drugalcdep.2022.109385 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ 44.39 Toxikologie VZ AR 233 2022 1 0401 0 |
| allfields_unstemmed |
10.1016/j.drugalcdep.2022.109385 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001760.pica (DE-627)ELV057207119 (ELSEVIER)S0376-8716(22)00122-3 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl Naumann, Rebecca B. verfasserin aut Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier “Lock-in” programs are used by health insurers to reduce the risk of adverse outcomes that can result from overutilization of opioids and other controlled substances. We estimated the association between North Carolina’s Medicaid lock-in program and use of opioid use disorder treatment-related services and naloxone dispensing. Lock-in Elsevier Beneficiary management Elsevier Naloxone Elsevier Treatment Elsevier Patient review and restriction Elsevier Opioid Elsevier Austin, Anna E. oth Wang, Lily oth Roberts, Andrew W. oth Enthalten in Elsevier Science Clark, Matthew ELSEVIER Statistical analysis to identify biomarkers for safety 2018 an international journal on biomedical and psychosocial approaches Amsterdam [u.a.] (DE-627)ELV000553670 volume:233 year:2022 day:1 month:04 pages:0 https://doi.org/10.1016/j.drugalcdep.2022.109385 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ 44.39 Toxikologie VZ AR 233 2022 1 0401 0 |
| allfieldsGer |
10.1016/j.drugalcdep.2022.109385 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001760.pica (DE-627)ELV057207119 (ELSEVIER)S0376-8716(22)00122-3 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl Naumann, Rebecca B. verfasserin aut Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier “Lock-in” programs are used by health insurers to reduce the risk of adverse outcomes that can result from overutilization of opioids and other controlled substances. We estimated the association between North Carolina’s Medicaid lock-in program and use of opioid use disorder treatment-related services and naloxone dispensing. Lock-in Elsevier Beneficiary management Elsevier Naloxone Elsevier Treatment Elsevier Patient review and restriction Elsevier Opioid Elsevier Austin, Anna E. oth Wang, Lily oth Roberts, Andrew W. oth Enthalten in Elsevier Science Clark, Matthew ELSEVIER Statistical analysis to identify biomarkers for safety 2018 an international journal on biomedical and psychosocial approaches Amsterdam [u.a.] (DE-627)ELV000553670 volume:233 year:2022 day:1 month:04 pages:0 https://doi.org/10.1016/j.drugalcdep.2022.109385 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ 44.39 Toxikologie VZ AR 233 2022 1 0401 0 |
| allfieldsSound |
10.1016/j.drugalcdep.2022.109385 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001760.pica (DE-627)ELV057207119 (ELSEVIER)S0376-8716(22)00122-3 DE-627 ger DE-627 rakwb eng 610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl Naumann, Rebecca B. verfasserin aut Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier “Lock-in” programs are used by health insurers to reduce the risk of adverse outcomes that can result from overutilization of opioids and other controlled substances. We estimated the association between North Carolina’s Medicaid lock-in program and use of opioid use disorder treatment-related services and naloxone dispensing. Lock-in Elsevier Beneficiary management Elsevier Naloxone Elsevier Treatment Elsevier Patient review and restriction Elsevier Opioid Elsevier Austin, Anna E. oth Wang, Lily oth Roberts, Andrew W. oth Enthalten in Elsevier Science Clark, Matthew ELSEVIER Statistical analysis to identify biomarkers for safety 2018 an international journal on biomedical and psychosocial approaches Amsterdam [u.a.] (DE-627)ELV000553670 volume:233 year:2022 day:1 month:04 pages:0 https://doi.org/10.1016/j.drugalcdep.2022.109385 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA 44.38 Pharmakologie VZ 44.39 Toxikologie VZ AR 233 2022 1 0401 0 |
| language |
English |
| source |
Enthalten in Statistical analysis to identify biomarkers for safety Amsterdam [u.a.] volume:233 year:2022 day:1 month:04 pages:0 |
| sourceStr |
Enthalten in Statistical analysis to identify biomarkers for safety Amsterdam [u.a.] volume:233 year:2022 day:1 month:04 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Pharmakologie Toxikologie |
| institution |
findex.gbv.de |
| topic_facet |
Lock-in Beneficiary management Naloxone Treatment Patient review and restriction Opioid |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Statistical analysis to identify biomarkers for safety |
| authorswithroles_txt_mv |
Naumann, Rebecca B. @@aut@@ Austin, Anna E. @@oth@@ Wang, Lily @@oth@@ Roberts, Andrew W. @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000553670 |
| dewey-sort |
3610 |
| id |
ELV057207119 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV057207119</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625001147.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.drugalcdep.2022.109385</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001760.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV057207119</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0376-8716(22)00122-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">15,3</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PHARM</subfield><subfield code="q">DE-84</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.39</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Naumann, Rebecca B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">“Lock-in” programs are used by health insurers to reduce the risk of adverse outcomes that can result from overutilization of opioids and other controlled substances. We estimated the association between North Carolina’s Medicaid lock-in program and use of opioid use disorder treatment-related services and naloxone dispensing.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lock-in</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Beneficiary management</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Naloxone</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Patient review and restriction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Opioid</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Austin, Anna E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Lily</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roberts, Andrew W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Clark, Matthew ELSEVIER</subfield><subfield code="t">Statistical analysis to identify biomarkers for safety</subfield><subfield code="d">2018</subfield><subfield code="d">an international journal on biomedical and psychosocial approaches</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000553670</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:233</subfield><subfield code="g">year:2022</subfield><subfield code="g">day:1</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.drugalcdep.2022.109385</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-PHARM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.38</subfield><subfield code="j">Pharmakologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.39</subfield><subfield code="j">Toxikologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">233</subfield><subfield code="j">2022</subfield><subfield code="b">1</subfield><subfield code="c">0401</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Naumann, Rebecca B. |
| spellingShingle |
Naumann, Rebecca B. ddc 610 ssgn 15,3 fid PHARM bkl 44.38 bkl 44.39 Elsevier Lock-in Elsevier Beneficiary management Elsevier Naloxone Elsevier Treatment Elsevier Patient review and restriction Elsevier Opioid Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing |
| authorStr |
Naumann, Rebecca B. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000553670 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing Lock-in Elsevier Beneficiary management Elsevier Naloxone Elsevier Treatment Elsevier Patient review and restriction Elsevier Opioid Elsevier |
| topic |
ddc 610 ssgn 15,3 fid PHARM bkl 44.38 bkl 44.39 Elsevier Lock-in Elsevier Beneficiary management Elsevier Naloxone Elsevier Treatment Elsevier Patient review and restriction Elsevier Opioid |
| topic_unstemmed |
ddc 610 ssgn 15,3 fid PHARM bkl 44.38 bkl 44.39 Elsevier Lock-in Elsevier Beneficiary management Elsevier Naloxone Elsevier Treatment Elsevier Patient review and restriction Elsevier Opioid |
| topic_browse |
ddc 610 ssgn 15,3 fid PHARM bkl 44.38 bkl 44.39 Elsevier Lock-in Elsevier Beneficiary management Elsevier Naloxone Elsevier Treatment Elsevier Patient review and restriction Elsevier Opioid |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a e a ae aea l w lw a w r aw awr |
| hierarchy_parent_title |
Statistical analysis to identify biomarkers for safety |
| hierarchy_parent_id |
ELV000553670 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Statistical analysis to identify biomarkers for safety |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000553670 |
| title |
Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing |
| ctrlnum |
(DE-627)ELV057207119 (ELSEVIER)S0376-8716(22)00122-3 |
| title_full |
Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing |
| author_sort |
Naumann, Rebecca B. |
| journal |
Statistical analysis to identify biomarkers for safety |
| journalStr |
Statistical analysis to identify biomarkers for safety |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Naumann, Rebecca B. |
| container_volume |
233 |
| class |
610 VZ 15,3 ssgn PHARM DE-84 fid 44.38 bkl 44.39 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Naumann, Rebecca B. |
| doi_str_mv |
10.1016/j.drugalcdep.2022.109385 |
| dewey-full |
610 |
| title_sort |
impacts of a medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing |
| title_auth |
Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing |
| abstract |
“Lock-in” programs are used by health insurers to reduce the risk of adverse outcomes that can result from overutilization of opioids and other controlled substances. We estimated the association between North Carolina’s Medicaid lock-in program and use of opioid use disorder treatment-related services and naloxone dispensing. |
| abstractGer |
“Lock-in” programs are used by health insurers to reduce the risk of adverse outcomes that can result from overutilization of opioids and other controlled substances. We estimated the association between North Carolina’s Medicaid lock-in program and use of opioid use disorder treatment-related services and naloxone dispensing. |
| abstract_unstemmed |
“Lock-in” programs are used by health insurers to reduce the risk of adverse outcomes that can result from overutilization of opioids and other controlled substances. We estimated the association between North Carolina’s Medicaid lock-in program and use of opioid use disorder treatment-related services and naloxone dispensing. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-PHARM SSG-OLC-PHA SSG-OPC-PHA |
| title_short |
Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing |
| url |
https://doi.org/10.1016/j.drugalcdep.2022.109385 |
| remote_bool |
true |
| author2 |
Austin, Anna E. Wang, Lily Roberts, Andrew W. |
| author2Str |
Austin, Anna E. Wang, Lily Roberts, Andrew W. |
| ppnlink |
ELV000553670 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.drugalcdep.2022.109385 |
| up_date |
2024-07-06T22:34:51.945Z |
| _version_ |
1803870841807568896 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV057207119</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625001147.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.drugalcdep.2022.109385</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001760.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV057207119</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0376-8716(22)00122-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">15,3</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PHARM</subfield><subfield code="q">DE-84</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.39</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Naumann, Rebecca B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Impacts of a Medicaid “lock-in” program on opioid use disorder treatment and services and naloxone dispensing</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">“Lock-in” programs are used by health insurers to reduce the risk of adverse outcomes that can result from overutilization of opioids and other controlled substances. We estimated the association between North Carolina’s Medicaid lock-in program and use of opioid use disorder treatment-related services and naloxone dispensing.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lock-in</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Beneficiary management</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Naloxone</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Patient review and restriction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Opioid</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Austin, Anna E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Lily</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roberts, Andrew W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Clark, Matthew ELSEVIER</subfield><subfield code="t">Statistical analysis to identify biomarkers for safety</subfield><subfield code="d">2018</subfield><subfield code="d">an international journal on biomedical and psychosocial approaches</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000553670</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:233</subfield><subfield code="g">year:2022</subfield><subfield code="g">day:1</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.drugalcdep.2022.109385</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-PHARM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.38</subfield><subfield code="j">Pharmakologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.39</subfield><subfield code="j">Toxikologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">233</subfield><subfield code="j">2022</subfield><subfield code="b">1</subfield><subfield code="c">0401</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.4007587 |